Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegfilgrastim biosimilar - Dong-A ST

Next Previous
Drug Profile

Pegfilgrastim biosimilar - Dong-A ST

Alternative Names: DA-3031; Dulastin; PEG-filgrastim - Dong-A; PEG-G-CSF - Dong-A; Pegfilgrastim biosimilar - Dong-A; Pegylated-G-CSF - Dong-A; Tripegfilgrastim; Tripegfilgrastim - Dong-A

Latest Information Update: 25 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Proteins; Radioprotectives; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Neutropenia

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Neutropenia(In adolescents, In children, Chemotherapy-induced) in South Korea (SC, Injection)
  • 01 Nov 2018 Dong-A completes a phase I trial in Neutropenia (In children, In adolescents, Chemotherapy-induced) in South Korea (SC) (NCT02963389)
  • 01 Sep 2016 Phase-I clinical trials in Neutropenia (In children, In adolescents, Chemotherapy-induced) in South Korea (SC) (NCT02963389)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top